Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3260482 | 0.77 | NOTUM (1.00) | NOTUMALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3491824 | 0.75 | NOTUM (0.61) | NOTUMALDH1A1KDM4EATML3MBTL1 | |
| SCHEMBL5151074 | 0.74 | HTT (0.42) | NOTUMALDH1A1KDM4EHPGDHTT | |
| SCHEMBL11453643 | 0.74 | NOTUM (0.65) | NOTUMALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL1494701 | 0.72 | NOTUM (0.49) | NOTUMALDH1A1KDM4EHPGDNR4A2 | |
| SCHEMBL3492555 | 0.72 | NR4A2 (0.56) | NOTUMALDH1A1KDM4ENR4A2MEN1 | |
| SCHEMBL35210145 | 0.70 | ALDH1A1 (0.35) | NOTUMALDH1A1KDM4EHPGDKMT2A | |
| SCHEMBL28931676 | 0.70 | NOTUM (0.68) | NOTUMALDH1A1KDM4EHPGDMEN1 | |
| SCHEMBL10998702 | 0.70 | NR4A3 (0.59) | ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL15506073 | 0.69 | CA12 (0.51) | NOTUMALDH1A1KDM4EHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671049-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | GSK3B, GSK3A, PYGB | NOTUM 731/4885ALDH1A1 3907/4885KDM4E 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.